Teva begins Phase IV Azilect mild cognitive impairment trial

The study will evaluate the cognitive function in adults with mild cognitive impairment in Parkinson's disease.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced that it has enrolled the first patient in the Phase IV clinical trial of Azilect. The study will evaluate the cognitive function in adults with mild cognitive impairment in Parkinson's disease.

The study will evaluate the effect of Azilect on cognitive function in adults with mild cognitive impairment in Parkinson's, as assessed by the Scales for Outcomes of Parkinson's Disease-Cognition after 24 weeks of treatment. The study includes 170 patients at 30 sites in the US.

“Cognitive impairment in Parkinson's disease is a major cause of disability and increased care partner burden,” said Dr. Robert A. Hauser, director of the Parkinson's Disease & Movement Disorders Center at the University of South Florida, the co-primary investigator of the study. “As currently there are no available treatments for cognitive impairment in Parkinson's disease, any therapy that may demonstrate benefit would be welcomed for this significant unmet need."

Teva chief scientific officer and president Global R&D Dr. Michael Hayden said, “Mild cognitive impairment in Parkinson's disease is common in non-demented Parkinson's patients and is associated with increasing age, disease duration and disease severity."

Published by Globes [online], Israel business news - www.globes-online.com - on February 5, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Twitter Facebook Linkedin RSS Newsletters גלובס